Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1993 Sep;68(3):537–539. doi: 10.1038/bjc.1993.382

Bioavailability and feasibility of subcutaneous 5-fluorouracil.

M M Borner 1, J Kneer 1, C Crevoisier 1, K W Brunner 1, T Cerny 1
PMCID: PMC1968410  PMID: 8353044

Abstract

Continuous intravenous (i.v.) infusion of 5-fluorouracil (5-FU) has been shown to be superior to bolus regimens in terms of response rates and toxicity. However, a continuous infusion is more expensive and prone to complications such as thromboembolism and infections. A way to circumvent these problems would be to administer 5-FU subcutaneously (s.c.). To assess feasibility and bioavailability of s.c. 5-FU, eight patients with advanced cancer received 250 mg 5-FU as an infusion over 90 min either intravenously (i.v.) or s.c. into the abdominal wall. The mean +/- s.d. bioavailability of s.c. 5-FU was 0.89 +/- 0.23. The interpatient variability for the area under the plasma concentration-time curve was 48% for the s.c. and 36% for the i.v. infusion. No local side effects were observed. To test the local tolerance of a more prolonged administration three patients received 930-1,000 mg m-2 5-FU by 24-h continuous s.c. infusion. The steady-state plasma levels were comparable to i.v. infusion. One patient developed a painless skin pigmentation at the s.c. infusion site. However, the same reaction was observed at the forearm after i.v. infusion. We conclude that at the dose studied s.c. 5-FU has an almost complete bioavailability and is well tolerated. Further work will show, whether prolonged s.c. infusion can be used as a safe and economical alternative to i.v. infusion.

Full text

PDF
537

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Al-Sarraf M. Head and neck cancer: chemotherapy concepts. Semin Oncol. 1988 Feb;15(1):70–85. [PubMed] [Google Scholar]
  2. Bruckner H. W., Motwani B. T. Chemotherapy of advanced cancer of the colon and rectum. Semin Oncol. 1991 Oct;18(5):443–461. [PubMed] [Google Scholar]
  3. Cerny T., Küpfer A., Zeugin T., Brunner K. W. Bioavailability of subcutaneous ifosfamide and feasibility of continuous outpatient application in cancer patients. Ann Oncol. 1990 Sep;1(5):365–368. doi: 10.1093/oxfordjournals.annonc.a057775. [DOI] [PubMed] [Google Scholar]
  4. Collins J. M., Dedrick R. L., King F. G., Speyer J. L., Myers C. E. Nonlinear pharmacokinetic models for 5-fluorouracil in man: intravenous and intraperitoneal routes. Clin Pharmacol Ther. 1980 Aug;28(2):235–246. doi: 10.1038/clpt.1980.156. [DOI] [PubMed] [Google Scholar]
  5. Dreyfuss A. I., Clark J. R., Wright J. E., Norris C. M., Jr, Busse P. M., Lucarini J. W., Fallon B. G., Casey D., Andersen J. W., Klein R. Continuous infusion high-dose leucovorin with 5-fluorouracil and cisplatin for untreated stage IV carcinoma of the head and neck. Ann Intern Med. 1990 Feb 1;112(3):167–172. doi: 10.7326/0003-4819-112-3-167. [DOI] [PubMed] [Google Scholar]
  6. Hansen R. M., Quebbeman E., Anderson T. 5-Fluorouracil by protracted venous infusion. A review of current progress. Oncology. 1989;46(4):245–250. doi: 10.1159/000226725. [DOI] [PubMed] [Google Scholar]
  7. Huan S., Pazdur R., Singhakowinta A., Samal B., Vaitkevicius V. K. Low-dose continuous infusion 5-fluorouracil. Evaluation in advanced breast carcinoma. Cancer. 1989 Feb 1;63(3):419–422. doi: 10.1002/1097-0142(19890201)63:3<419::aid-cncr2820630303>3.0.co;2-z. [DOI] [PubMed] [Google Scholar]
  8. Kish J. A., Ensley J. F., Jacobs J., Weaver A., Cummings G., Al-Sarraf M. A randomized trial of cisplatin (CACP) + 5-fluorouracil (5-FU) infusion and CACP + 5-FU bolus for recurrent and advanced squamous cell carcinoma of the head and neck. Cancer. 1985 Dec 15;56(12):2740–2744. doi: 10.1002/1097-0142(19851215)56:12<2740::aid-cncr2820561203>3.0.co;2-y. [DOI] [PubMed] [Google Scholar]
  9. Kish J. A., Weaver A., Jacobs J., Cummings G., Al-Sarraf M. Cisplatin and 5-fluorouracil infusion in patients with recurrent and disseminated epidermoid cancer of the head and neck. Cancer. 1984 May 1;53(9):1819–1824. doi: 10.1002/1097-0142(19840501)53:9<1819::aid-cncr2820530903>3.0.co;2-r. [DOI] [PubMed] [Google Scholar]
  10. Lokich J. J., Ahlgren J. D., Gullo J. J., Philips J. A., Fryer J. G. A prospective randomized comparison of continuous infusion fluorouracil with a conventional bolus schedule in metastatic colorectal carcinoma: a Mid-Atlantic Oncology Program Study. J Clin Oncol. 1989 Apr;7(4):425–432. doi: 10.1200/JCO.1989.7.4.425. [DOI] [PubMed] [Google Scholar]
  11. Macdonald J. S. Continuous low-dose infusion of fluorouracil: is the benefit worth the cost? J Clin Oncol. 1989 Apr;7(4):412–414. doi: 10.1200/JCO.1989.7.4.412. [DOI] [PubMed] [Google Scholar]
  12. Seifert P., Baker L. H., Reed M. L., Vaitkevicius V. K. Comparison of continuously infused 5-fluorouracil with bolus injection in treatment of patients with colorectal adenocarcinoma. Cancer. 1975 Jul;36(1):123–128. doi: 10.1002/1097-0142(197507)36:1<123::aid-cncr2820360108>3.0.co;2-c. [DOI] [PubMed] [Google Scholar]
  13. Stetson P. L., Shukla U. A., Ensminger W. D. Sensitive high-performance liquid chromatographic method for the determination of 5-fluorouracil in plasma. J Chromatogr. 1985 Nov 8;344:385–390. doi: 10.1016/s0378-4347(00)82045-9. [DOI] [PubMed] [Google Scholar]
  14. Vokes E. E., Schilsky R. L., Choi K. E., Magid D. M., Guarnieri C. M., Whaling S. M., Ratain M. J., Weichselbaum R. R., Panje W. R. A randomized study of inpatient versus outpatient continuous infusion chemotherapy for patients with locally advanced head and neck cancer. Cancer. 1989 Jan 1;63(1):30–36. doi: 10.1002/1097-0142(19890101)63:1<30::aid-cncr2820630105>3.0.co;2-m. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES